Loading
CatenaBio
CatenaBio is a California company that joins two different cancer-killing drugs onto one antibody, so a single medicine can attack a tumour in two ways. Its lead medicine, CATB-101, targets TROP2 and is in laboratory and animal testing.
Also called: Catena BiosciencesCatena Biosciences, Inc.
Overview
CatenaBio (Catena Biosciences) develops multi-payload antibody-drug conjugates with its CysTyr conjugation platform, which links proteins to payloads through cysteine and tyrosine; its science was invented in the laboratories of Jennifer Doudna and Matt Francis at UC Berkeley, and Marco Lobba is chief executive and co-founder. Its pipeline focuses on dual-payload conjugates for solid tumours, led by CATB-101, which targets TROP2; its NCI award funds HER2-targeted multi-payload conjugates. In fiscal year 2026 NCI awarded it USD 1,072,102 under SBIR award 1R44CA314761-01 for site-selective multi-payload HER2-targeted conjugates in breast and gastric cancers.
Headquarters
El Cerrito, CA, US
Scorecard
All companies#674of 1706 companies, score 4
- targets +2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 1R44CA314761-01: Advancing Site-Selective Multi-Payload HER2-Targeted Conjugates to Overcome Resistance and Boost Survival in Breast and Gastric Cancers | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1PreclinicalADC
CATB-101 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.
Notes
- CATB-101 is named in the existing record catb-101 (AACR 2026 abstract), not on the company's pipeline page, which shows the programmes as an image. Read on catenabio.com and NIH RePORTER on 4 November 2026.
Connected
6Similar pages
- TreatmentCAN020
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
- TreatmentCBB-120
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
- TreatmentCTPH-03
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
- TreatmentKH815
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
- TrialKH815 first-in-human study
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
- TreatmentASP2998
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
- CompanyT-E Meds
Shares Dual-payload ADC, HER2, Antibody-drug conjugate (ADC).
- CompanyAxcynsis Therapeutics
Shares Dual-payload ADC, HER2, Antibody-drug conjugate (ADC).
fronts
technologies
targets
drugs
PreclinicalADC
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
catenabio.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/